MP-214 3mg

DRUG3 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Schizophrenia

Phase 2

Safety and Efficacy of MP-214 in Patients With Schizophrenia

CompletedNCT01625000

Tanabe Pharma CorporationSchizophrenia

Start: 2012-05-31End: 2015-10-31Updated: 2026-01-05

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

CompletedNCT01626859

Tanabe Pharma CorporationSchizophrenia

Start: 2012-05-31End: 2013-08-31Updated: 2026-01-05

Long-Term Study of MP-214 in Patients With Schizophrenia

CompletedNCT01626872

Tanabe Pharma CorporationSchizophrenia

Start: 2012-09-30End: 2016-10-31Updated: 2026-01-05